Radiation Therapy for Chordoma and Chondrosarcoma of the Skull Base and the Cervical Spine

Noël, Georges; Habrand, Jean‐Louis; Jauffret, E; Crevoisier, R. de; Dederke, Sygon; Mammar, Hamid; Haie-Méder, Christine; Pontvert, D.; Hasboun, Dominique; Ferrand, R.; Boisserie, G.; Beaudré, A.; Gaboriaud, G.; Guedea, Ferrán; Petriz, L.; Mazeron, Jean‐Jacques

doi:10.1007/s00066-003-1065-5

Cited by 164 publications

(78 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45 Those results are in keeping with other published series. 16,46,47 Thus, it appears that the risk of local recurrence and subsequent death is more neutral with regard to sex than initially assumed. In the previous SEER analysis, the impact on outcomes from various clinical and therapeutic characteristics was assessed.…”

Section: Sex and Survivalmentioning

confidence: 99%

“…[15][16][17][18][19] Various prognostic factors, including but not limited to sex, [20][21][22][23] age, 15,16 and tumor volume, 16,22,[24][25][26] have been identified for this neoplasm, but the clinical significance remains questionable, because these findings are not consistent. For instance, female sex has been suggested as a negative prognostic feature in some but not all studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and relative survival of chordomas

Smoll

Gautschi

Radovanović

et al. 2013

Cancer

167

View full text Add to dashboard Cite

BACKGROUND: Chordomas are rare bone tumors arising from remnants of the embryonic notochord. METHODS: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to calculate the incidence, relative survival (RS), and standardized mortality ratio (SMR) of patients diagnosed with intracranial and extracranial chordomas and to assess the effects of age and sex on this disease. RESULTS: The overall incidence of extracranial and intracranial chordomas was 8.4 per 10 million population. The median overall survival of patients with chordoma patients was 7.7 years. The median survival was 7.7 years for male patients and 7.8 years for female patients. Younger patients (aged <40 years) survived longer compared with older patients (10-year RS, 68% vs 43%). The estimated age-standardized 5-year, 10-year, and 20-year RS rates was 72%, 48%, and 31%, respectively. The SMR in the overall cohort was 4.6 (95% confidence interval, 4.22-5.0) or 21.0 (95% confidence interval, 16.6-27.2) in young adult patients and 3.0 (95% confidence interval, 2.6-3.4) in elderly patients. CONCLUSIONS: The elderly had a more aggressive form of this disease; and, other than the incidence, sex did not influence outcome in this disease. The study of chordomas presents a good case for the contribution that the SMR can have on measuring the impact of a disease on a population of patients. Although the younger population has better survival rates, the impact (SMR) in the younger age groups is much higher than in older populations.

show abstract

Section: Sex and Survivalmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and relative survival of chordomas

Smoll

Gautschi

Radovanović

et al. 2013

Cancer

167

View full text Add to dashboard Cite

show abstract

“…[15][16][17] Note that in the above examples, the estimated treatment time for prostate cancer was for treating only one field per day, and the estimated treatment time for lung cancer was for performing the gating technique after fluoroscopy using two or more treatment fields every day. It should be noted that these were not actual treatment times.…”

Section: Treatment Time By Disease Sitementioning

confidence: 99%

Analysis of Treatment and Delay Times by Disease Site and Delivery Technique at Samsung Medical Center: Proton Therapy Center

Ahn

Chung

et al. 2016

Prog Med Phys

View full text Add to dashboard Cite

cc This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Moreover, we analyze the number of incidents causing treatment delays and the corresponding treatment delay time. The mal-functioning related to the X-ray imagers was the main reason for delays in the wobbling treatment; the delayed time decreased continually from January to June 2016, due to the attaining of proficiency in handling the mal-functioning. The main reason for delays in the scanning treatment was interlocks during scanning pattern delivery; and the interlocks has been resolved by proton therapy service engineers. Through this work, we hope to provide other institutes with useful information and insight for initial operation of proton therapy system. Analysis of Treatment and

show abstract

“…Foton-proton veya sadece proton protokolleriyle (79 CGE'ye kadar dozlarla) lokal kontrol oranlarını %85-100 arasında, sınırlı oranda ciddi yan etki ile bildiren çalışmalar vardır. [48][49][50] Karbon iyonları veya diğer yüklü partiküllerle radyoterapi, diğer cazip radyasyon modaliteleridir. Bu modaliteler de protonun fiziksel özellikleri ile, daha yüksek radyobiyolojik aktiviteyi birleştirir.…”

Section: Genel Bilgilerunclassified

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Karakaya¹

2014

TOTBID

View full text Add to dashboard Cite

show abstract

Radiation Therapy for Chordoma and Chondrosarcoma of the Skull Base and the Cervical Spine

Cited by 164 publications

References 43 publications

Incidence and relative survival of chordomas

Incidence and relative survival of chordomas

Analysis of Treatment and Delay Times by Disease Site and Delivery Technique at Samsung Medical Center: Proton Therapy Center

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Contact Info

Product

Resources

About